Reply to the Letter to the Editor: “Effects of rifaximin in fructose-induced steatohepatitis in rats”
Nese Cabuk Celik, Rumeysa Yilmaz Goc, Ibrahim Halil Bahcecioglu, I. Hanifi Ozercan, Mehmet Tuzcu, Necip Ilhan, Kazim Sahin · 2026
Read Reply to the Letter to the Editor: “Effects of rifaximin in fructose-induced steatohepatitis in rats” by Nese Cabuk Celik, Rumeysa Yilmaz Goc, Ibrahim Halil Bahcecioglu, I. Hanifi Ozercan, Mehmet Tuzcu, Necip Ilhan, Kazim Sahin (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13473244.txt.
Description
Nese Cabuk Celik and colleagues answer a reader letter in 2026 about their rat study of rifaximin in fatty liver disease caused by fructose. Rifaximin is a gut-focused antibiotic drug. Critics had noted that the rat livers showed no scarring, which limits what the work can say. The authors agree, while noting that an early disease stage can still reveal drug effects cleanly.
The reply also explains why two dosing plans, once a week and three times a week, were both tried. Both plans helped, and neither proved clearly better than the other. That pattern hints that dosing can flex within this model, though the point needs more work. Longer studies with scarring present are named as the key next step.
Catalog record
| CREATOR | Nese Cabuk Celik, Rumeysa Yilmaz Goc, Ibrahim Halil Bahcecioglu, I. Hanifi Ozercan, Mehmet Tuzcu, Necip Ilhan, Kazim Sahin |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |